

513  
A1

(a) measuring levels of CC2 in cells, tissues or  
5 bodily fluids in a patient; and

10

15

(b) measuring CC2 levels in a sample of cells, tissues, or bodily fluid from said patient; and

20

25

(b) measuring CC2 levels in a sample of cells, tissue, or bodily fluid from said patient; and

30

- 24 -

measured CC2 levels is associated with a cancer which is regressing or in remission.

4. A method of monitoring a gastrointestinal cancer in a patient for the onset of metastasis comprising:

- 5 (a) identifying a patient having a gastrointestinal cancer that is not known to have metastasized;
- (b) periodically measuring levels of CC2 in samples of cells, tissues, or bodily fluid from said patient; and
- 10 (c) comparing the periodically measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CC2 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

15 5. A method of monitoring a change in stage of a gastrointestinal cancer in a patient comprising:

- (a) identifying a patient having a gastrointestinal cancer;
- (b) periodically measuring levels of CC2 in cells, 20 tissues, or bodily fluid from said patient; and
- (c) comparing the periodically measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CC2 levels in the patient versus the 25 normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CC2 comprises SEQ ID NO:1 or SEQ ID NO:2.

30 7. An antibody which specifically binds CC2.

- 25 -

8. A method of imaging a gastrointestinal cancer in a patient comprising administering to the patient an antibody of claim 7.

9. The method of claim 8 wherein said antibody is  
5 labeled with paramagnetic ions or a radioisotope.

10. A method of treating a gastrointestinal cancer in a patient comprising administering to the patient an antibody of claim 7.

11. The method of claim 10 wherein the antibody is  
10 conjugated to a cytotoxic agent.